Laboratory Evaluation for Hepatomegaly and Hepatic Steatosis
For hepatomegaly and hepatic steatosis, order an initial panel including bilirubin, albumin, ALT, ALP, GGT, and complete blood count, followed immediately by a comprehensive liver etiology screen that includes hepatitis B surface antigen, hepatitis C antibody, autoimmune markers (AMA, ASMA, ANA), serum immunoglobulins, ferritin, and transferrin saturation, along with abdominal ultrasound. 1
Initial Laboratory Panel
Start with these basic liver function tests 1:
- Bilirubin
- Albumin
- Alanine aminotransferase (ALT)
- Alkaline phosphatase (ALP)
- γ-glutamyltransferase (GGT)
- Complete blood count (if not done in past 12 months)
Critical caveat: Do not rely solely on abnormal liver enzymes to detect significant liver disease. ALT levels often fall as fibrosis progresses, and patients with cirrhosis frequently have normal ALT 2. The magnitude of enzyme elevation does not correlate with disease severity.
Comprehensive Liver Etiology Screen
Regardless of the degree or duration of abnormality, proceed with a full etiologic workup 1:
Infectious Workup
- Hepatitis B surface antigen
- Hepatitis C antibody (with reflex PCR if positive)
Autoimmune Markers
- Anti-mitochondrial antibody (AMA)
- Anti-smooth muscle antibody (ASMA)
- Antinuclear antibody (ANA)
- Serum immunoglobulins
Metabolic Screening
- Ferritin and transferrin saturation (drawn simultaneously to assess for hemochromatosis)
Imaging
- Abdominal ultrasound is part of the standard etiologic screen 1
Important limitation: Ultrasound has only 50% sensitivity and 61% specificity for steatohepatitis, and 40% sensitivity with 58% specificity for advanced fibrosis 2. While increased liver echogenicity correctly identifies moderate-to-severe steatosis in 87% of cases, it cannot reliably detect fibrosis or even cirrhosis 3.
Risk Stratification for Fibrosis
Once steatosis is identified or liver tests remain abnormal, immediately calculate non-invasive fibrosis scores 1, 2:
First-Line Fibrosis Assessment
Calculate FIB-4 or NAFLD Fibrosis Score (NFS) using routine lab values 1, 2:
FIB-4 thresholds:
- < 1.3 (or < 2.0 if age >65): Low probability of advanced fibrosis—reassure patient
- 1.3-2.67: Indeterminate risk—requires additional testing
- > 2.67: High risk—refer to hepatology
NFS thresholds:
- < -1.455 (or < 0.12 if age >65): Low probability of advanced fibrosis
- Indeterminate or high scores warrant further evaluation
Critical point: Neither FIB-4 nor NFS are validated in patients under 35 years old 2. Use caution interpreting these scores in younger patients.
Second-Line Testing for Indeterminate Risk
For patients in the indeterminate FIB-4 range, obtain 2, 4:
- Transient elastography (FibroScan)
- Enhanced Liver Fibrosis (ELF) test, or
- Ultrasound or MRI elastography
Algorithmic Approach
- Order initial panel (bilirubin, albumin, ALT, ALP, GGT, CBC)
- Order comprehensive etiology screen (hepatitis serologies, autoimmune markers, iron studies, immunoglobulins, ultrasound)
- Calculate FIB-4 or NFS from routine labs
- If FIB-4 < 1.3 (or < 2.0 if >65): Monitor, address metabolic risk factors
- If FIB-4 1.3-2.67: Order elastography or ELF test
- If FIB-4 > 2.67 or high-risk on second-line testing: Refer to hepatology
Additional Considerations
Metabolic risk factor assessment is essential 2:
- Fasting glucose or HbA1c
- Lipid panel (triglycerides, HDL, LDL)
- Assessment for metabolic syndrome components
Do not wait for repeat testing or "watch and wait" if initial workup suggests steatosis—the key predictor of mortality is advancing fibrosis, not the presence of steatosis itself 2. Early risk stratification prevents missed opportunities to identify patients with advanced disease who need specialist care.
The stratified approach using FIB-4 followed by elastography has demonstrated a 5-fold increase in detection of advanced fibrosis and 3-fold increase in cirrhosis detection compared to no structured pathway 2.